Dyslipidemia – Heveren-Healthcare https://heveren.com Trusted pharmaceutical solutions for a healthier tomorrow Sun, 06 Apr 2025 07:53:46 +0000 en-US hourly 1 https://heveren.com/wp-content/uploads/2022/06/cropped-theveren-logo-32x32.png Dyslipidemia – Heveren-Healthcare https://heveren.com 32 32 ROSAFIN F https://heveren.com/product/rosafin-f/ Sun, 06 Apr 2025 05:52:14 +0000 https://heveren.com/?post_type=product&p=1131 Indication : For the Management of Dyslipidemia.

Dyslipidemia a condition characterized by an abnormal level of lipids (such as cholesterol, triglycerides, LDL, and HDL) in the blood, which can increase the risk of cardiovascular disease, including heart attacks, strokes, and peripheral artery disease.

MOA : Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts -3-hydroxy-3- methyl glutaryl coenzyme A to mevalonate, a precursor of cholesterol. Activates peroxisome proliferator-activated receptor-alpha.

]]> ROSAFIN GOLD https://heveren.com/product/rosafin-gold/ Sun, 06 Apr 2025 05:44:00 +0000 https://heveren.com/?post_type=product&p=1126 Indication : For the Management of Dyslipidemia

Dyslipidemia a condition characterized by an abnormal level of lipids (such as cholesterol, triglycerides, LDL, and HDL) in the blood, which can increase the risk of cardiovascular disease, including heart attacks, strokes, and peripheral artery disease.

MOA : Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts -3-hydroxy-3- methyl glutaryl coenzyme A to mevalonate, a precursor of cholesterol. Aspirin is inhibitory of Thromboxane A2 and COX inhibitory. Clopidogrel Inhibits platelet activation and aggregation by irreversibly binding to P2Y12 receptor on platelets.

]]> ROSAFIN A https://heveren.com/product/rosafin-a/ Sun, 06 Apr 2025 05:35:19 +0000 https://heveren.com/?post_type=product&p=1120 Indication : For the Management of Dyslipidemia.

Dyslipidemia a condition characterized by an abnormal level of lipids (such as cholesterol, triglycerides, LDL, and HDL) in the blood, which can increase the risk of cardiovascular disease, including heart attacks, strokes, and peripheral artery disease.

MOA : Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts -3-hydroxy-3- methyl glutaryl coenzyme A to mevalonate, a precursor of cholesterol. Aspirin is inhibitory of Thromboxane A2 and COX inhibitory.

]]> ROSAFIN https://heveren.com/product/rosafin/ Sun, 06 Apr 2025 05:06:28 +0000 https://heveren.com/?post_type=product&p=1098 Indication : For the Management of Dyslipidemia.

Dyslipidemia a condition characterized by an abnormal level of lipids (such as cholesterol, triglycerides, LDL, and HDL) in the blood, which can increase the risk of cardiovascular disease, including heart attacks, strokes, and peripheral artery disease.

MOA : It is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts -3-hydroxy-3- methyl glutaryl coenzyme A to mevalonate, a precursor of cholesterol

]]>